New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Peptides and BPC 157 for Pain: PainExam Podcast Apple Podcasts FDA to weigh easing limits on unproven peptides Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law BPC 157 and TB 500: Uses and Safety ConsumerLab.com